Could early palliative care reduce aggressive End-of-Life cancer treatments?

NCT ID NCT07490106

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly assigned to either early integrated palliative care or usual care. The goal is to see if early collaboration between oncologists and palliative care doctors leads to less chemotherapy, fewer ER visits, and fewer ICU stays near death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

early integrated palliative care

What this could lead to

If successful, this could show that early palliative care helps patients with advanced cancer avoid harsh treatments at the end of life.

What could go wrong

This is an early-stage study (not yet recruiting) that measures care patterns, not survival. Results may not apply to all cancer types or healthcare systems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm female reproductive organ cancer head and neck cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Oscar Lambret

    Lille, 59020, France